Safety of GLP-1 Receptor Agonists in Patients with Elevated Amylase

Risk Assessment for Pancreatitis

• The American College of Cardiology notes that although post-marketing case reports suggested possible associations between GLP-1 RAs and acute pancreatitis, the LEADER trial did not demonstrate any increase in the risk of pancreatitis 1
• The FDA and European Medicines Agency have not identified a causal link between GLP-1 RAs and either pancreatitis or pancreatic cancer 1

Clinical Approach for Patients with Elevated Amylase

• If symptoms of pancreatitis develop, such as nausea and vomiting, discontinue GLP-1 RA and evaluate for pancreatitis 1
• Consider baseline risk factors, including history of pancreatitis, and use GLP-1 RAs with caution in these patients 1, 2

Monitoring Recommendations

• If a patient develops symptoms suggestive of pancreatitis, promptly evaluate with appropriate laboratory tests and imaging 1

Important Precautions

• Patients should be educated about symptoms of pancreatitis and instructed to seek medical attention if they develop 1
• Start with lower doses of GLP-1 RAs and titrate gradually to minimize gastrointestinal side effects 3